{"preliminary_commentary":{"by_channel":{"x_thread":2,"youtube":1},"note":"Preliminary. Indexed podcasts, YouTube videos and X posts that name this trial so far. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this."},"free_build":{"available":false},"commentary_summary":null,"drugs_tested":null,"indication":null,"name":"TARGET-D 201","nct_id":"NCT07644559","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=target-d-201-nct07644559. The price is an estimate of verified statements from the commentary indexed so far, fixed at order. Final coverage is set when the report is built. We build the report within 24 hours of confirming the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_usd":750,"size":"focused","size_rule":"Focused: 1–150 verified statements, estimated at 14 per indexed commentary source"},"registry":{"acronym":null,"arms":[{"description":null,"label":"VS-7375 Monotherapy","type":"EXPERIMENTAL"},{"description":null,"label":"VS-7375 + cetuximab 2L PDAC","type":"EXPERIMENTAL"},{"description":null,"label":"VS-7375 + cetuximab 1L PDAC","type":"EXPERIMENTAL"}],"collaborators":[],"completion_date":{"date":"2028-12","type":"ESTIMATED"},"conditions":["Pancreatic Ductal Adenocarcinoma (PDAC)","G12D Mutated KRAS"],"enrollment":{"count":185,"type":"ESTIMATED"},"has_results":false,"interventions":[{"name":"VS-7375","otherNames":[],"type":"DRUG"},{"name":"cetuximab (or panitumumab if α-gal IgE+ or cetuximab reaction)","otherNames":[],"type":"DRUG"}],"last_update":"2026-10-23","lead_sponsor":"Verastem, Inc.","official_title":"A Phase 2, Open-label Study of VS-7375, an Oral KRAS G12D (ON/OFF) Inhibitor, as Monotherapy and With Cetuximab, in Patients With Metastatic KRAS G12D-Mutated Pancreatic Cancer (TARGET-D 201)","overall_status":"RECRUITING","phases":["PHASE2"],"primary_completion_date":{"date":"2027-06","type":"ESTIMATED"},"primary_outcomes":[{"measure":"Confirmed ORR by blinded independent central review (BICR) per RESIST v1.1","timeFrame":"6 months"},{"measure":"To characterize the safety and tolerability of VS-7375 monotherapy or in combination with cetuximab, administered on a daily oral schedule in participants with KRAS G12D-mutated PDAC.","timeFrame":"6 months"}],"references":[],"start_date":{"date":"2026-06-16","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"A Phase 2 Study of VS-7375 in Patients With KRAS G12D-Mutated Pancreatic Cancer","url":"https://clinicaltrials.gov/study/NCT07644559"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"3.1","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/target-d-201-nct07644559"}